MAVENCLAD Drug Patent Profile

Which patents cover Mavenclad, and when can generic versions of Mavenclad launch?

Mavenclad is a drug marketed by Emd Serono Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred patent family members in thirty-one countries.

The generic ingredient in MAVENCLAD is cladribine. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cladribine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mavenclad

A generic version of MAVENCLAD was approved as cladribine by HIKMA on February 28^th, 2000.

Summary for MAVENCLAD

International Patents:	100
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	113
Clinical Trials:	12
Drug Prices:	Drug price information for MAVENCLAD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MAVENCLAD
What excipients (inactive ingredients) are in MAVENCLAD?	MAVENCLAD excipients list
DailyMed Link:	MAVENCLAD at DailyMed

See drug prices for MAVENCLAD

Recent Clinical Trials for MAVENCLAD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Leeds Teaching Hospitals NHS Trust	Phase 2/Phase 3
Queen Mary University of London	Phase 2/Phase 3
University of Edinburgh	Phase 2/Phase 3

See all MAVENCLAD clinical trials

Pharmacology for MAVENCLAD

Drug Class

Purine Antimetabolite

Paragraph IV (Patent) Challenges for MAVENCLAD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAVENCLAD	Tablets	cladribine	10 mg	022561	1	2022-04-07

US Patents and Regulatory Information for MAVENCLAD

MAVENCLAD is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	7,713,947
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	12,539,329
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	12,533,408

Expired US Patents for MAVENCLAD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	7,888,328
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	8,785,415

EU/EMA Drug Approvals for MAVENCLAD

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Europe B.V.	Mavenclad	cladribine	EMEA/H/C/004230Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.	Authorised	no	no	no	2017-08-22
Lipomed GmbH	Litak	cladribine	EMEA/H/C/000504Litak is indicated for the treatment of hairy-cell leukaemia.	Authorised	no	no	no	2004-04-14

International Patents for MAVENCLAD

See the table below for patents covering MAVENCLAD around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005318190	Cladribine regimen for treating multiple sclerosis
World Intellectual Property Organization (WIPO)	2019101960
South Korea	20070091662	CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS

Supplementary Protection Certificates for MAVENCLAD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1608344	C20180007 00334	Estonia		PRODUCT NAME: KLADRIBIIN;REG NO/DATE: EU/1/17/1212 24.08.2017
1827461	C01827461/01	Switzerland		PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66831 19.03.2019
1827461	18C1008	France		PRODUCT NAME: CLADRIBINE; REGISTRATION NO/DATE: EU/1/17/1212 20170824

Mavenclad Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is Mavenclad and its approved indications?

Mavenclad (cladribine) is a selective immune reconstitution therapy approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for relapsing multiple sclerosis (MS). It was developed by EMD Serono, a Merck KGaA division. The drug was approved in 2017 in Europe and in 2019 in the U.S.

Its primary indication is relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). Mavenclad is administered as a short course over two years, with doses divided into two treatment cycles during Year 1 and Year 2. Its unique dosing regimen distinguishes it from continuous immunosuppressants.

What are Mavenclad’s sales and revenue figures?

Since launch, Mavenclad's sales have seen gradual growth. The drug's revenue trajectory reflects uptake in targeted markets:

Year	Global Sales (USD millions)	Notes
2018	$60 million	Limited initial penetration, primarily in Europe
2019	$180 million	U.S. approval, increased adoption
2020	$375 million	Steady expansion, new markets entered
2021	$520 million	Broadening payer coverage, increased prescribing

Sales growth correlates with expanded approvals, increased clinician awareness, and positive real-world data. Notably, Merck KGaA reported sales of approximately €454 million (~$520 million) globally in 2021 for Mavenclad.

How do market dynamics influence Mavenclad’s trajectory?

Competitive landscape

Mavenclad competes with both oral and infusion disease-modifying therapies (DMTs). Key competitors include:

• Ocrevus (ocrelizumab): protein-based infusion, approved since 2017.
• Aubagio (teriflunomide): oral, approved since 2012.
• Tecfidera (dimethyl fumarate): oral, approved since 2013.

Mavenclad's short-course regimen offers advantages over long-term daily or weekly treatments, appealing to patients seeking convenience and reduced exposure to immunosuppression risks. However, concerns about malignancy risks influence prescribing patterns.

Regulatory and reimbursement environment

Regulatory decisions impact market access. The EMA approved Mavenclad for relapsing MS in 2017, with specific restrictions due to safety concerns over malignancy. The FDA approved it in 2019 with boxed warnings and contraindications, affecting clinician adoption. Reimbursement policies vary; coverage improves with real-world safety data.

Patient and clinician acceptance

Prescribing remains cautious owing to safety profile, especially the risk of infections and malignancies. Treatment adherence benefits from the drug's convenience. Ongoing education and post-marketing surveillance are critical to growth.

Geographic expansion

Growth potential hinges on approval in additional markets, notably Asia-Pacific and Latin America. Imports or licensing agreements influence regional access.

What are the key drivers of Mavenclad's financial performance?

1. Regulatory approvals: Expandable indications and markets directly enhance sales capacity.
2. Safety profile management: Ongoing data and risk mitigation improve acceptance.
3. Market penetration: Increasing utilization within existing markets boosts revenue.
4. Pricing strategies: Tiered pricing and rebates impact gross margins.
5. Pipeline and line extensions: Potential for combination therapies and new indications could boost long-term revenues.

Risks and challenges impacting financial outcomes

• Safety concerns: Malignancy warnings limit prescription volume.
• Market share competition: Sustained dominance may be challenged by newer oral agents.
• Pricing pressure: Payers demand discounts amid tight budgets.
• Market access barriers: Regulatory delays or restrictions could slow revenue growth.
• Patent life: Patent expiration planned for 2027 in the U.S., risking generic competition unless secondary patents or line extensions are secured.

Future outlook and growth opportunities

Revenue projections suggest a compound annual growth rate (CAGR) of approximately 15–20% from 2022 through 2025, driven by expanding approvals, increased clinician confidence, and potential new indications such as primary progressive MS. The development pipeline includes ongoing trials for other autoimmune conditions.

Key Takeaways

• Mavenclad has demonstrated steady revenue growth since 2017, reaching approximately $520 million in 2021.
• Its short-course, oral regimen appeals in a competitive MS market but faces safety-related prescribing restrictions.
• Expansion depends on regulatory approvals, reimbursement, and overcoming safety concerns.
• The drug's patent lifecycle and pipeline developments will influence long-term financial performance.
• Competitive dynamics and payer policies remain primary risk factors.

Frequently Asked Questions

1. What are the main safety concerns associated with Mavenclad?
Malignancy risk, infections, and lymphopenia are primary safety concerns that led to boxed warnings and restricted indications.

2. How does Mavenclad compare to other MS therapies in terms of convenience?
Its two-year, short-course regimen offers a dosing advantage over continuous oral or infusion therapies, potentially improving adherence.

3. What markets are expected to expand Mavenclad's revenue base?
Asia-Pacific, Latin America, and additional European approvals offer growth avenues contingent on regulatory decisions.

4. When is patent expiry, and what are the implications?
Patents protecting Mavenclad will expire around 2027 in the U.S., risking generic competition unless secondary patents are secured.

5. What is the potential for new indications?
Clinical trials are ongoing for primary progressive MS and other autoimmune diseases, presenting opportunities for line extensions and revenue diversification.

---

References

1. Merck KGaA (2022). Mavenclad sales report.
2. EMA (2017). Summary of opinion for Mavenclad approval.
3. FDA (2019). Mavenclad (cladribine) approval letter.
4. IQVIA (2022). MS treatment market analysis.
5. ClinicalTrials.gov (2022). Ongoing studies related to Mavenclad.